Title : PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Pub. Date : 2013 Apr

PMID : 23275151






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. veliparib ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens
2 Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. veliparib ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens